Latest Content

Telehealth has quickly become a central part of the mental health system among younger, higher-income, college-educated, and privately insured patients.

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and offering convenient self-injection treatment.

Ryan Haumschild, PharmD, MS, MBA, discusses key considerations for pharmacists to ensure access to cutting-edge therapies for patients with cancer.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.